Thus, MODY10′s clinical spectrum—from neonatal diabetes to adult-onset hyperglycemia—is dictated by mutation-specific disruptions in proinsulin folding, trafficking, and ER homeostasis. The gene discussed is INS; the disease is Hyperglycemia.